These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 24577874)

  • 21. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
    Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
    Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.
    Buchler T; Bortlicek Z; Poprach A; Kubackova K; Kiss I; Zemanova M; Fiala O; Dusek L; Vyzula R; Melichar B;
    Urol Oncol; 2014 Jul; 32(5):569-75. PubMed ID: 24629497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
    Miyazaki A; Miyake H; Harada K; Fujisawa M
    Anticancer Res; 2015 May; 35(5):3067-73. PubMed ID: 25964597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
    Bracarda S; Bellmunt J; Melichar B; Négrier S; Bajetta E; Ravaud A; Sneller V; Escudier B
    BJU Int; 2011 Jan; 107(2):214-9. PubMed ID: 20942831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
    Harshman LC; Barbeau S; McMillian A; Srinivas S
    Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study.
    Bergmann L; Goebell PJ; Kube U; Kindler M; Herrmann E; Janssen J; Schmitz J; Weikert S; Steiner G; Jakob A; Staehler MD; Steiner T; Overkamp F; Albrecht M; Guderian G; Doehn C
    Onkologie; 2013; 36(3):95-100. PubMed ID: 23485996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
    Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
    J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
    Guo J; Huang Y; Zhang X; Zhou F; Sun Y; Qin S; Ye Z; Wang H; Jappe A; Straub P; Pirotta N; Gogov S
    BMC Cancer; 2013 Mar; 13():136. PubMed ID: 23514360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
    Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Kay A; Ravaud A;
    Cancer; 2010 Sep; 116(18):4256-65. PubMed ID: 20549832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
    Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
    Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis.
    Bracarda S; Hutson TE; Porta C; Figlin RA; Calvo E; Grünwald V; Ravaud A; Motzer R; Kim D; Anak O; Panneerselvam A; Escudier B
    Br J Cancer; 2012 Apr; 106(9):1475-80. PubMed ID: 22441644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.
    Gore ME; Jones RJ; Ravaud A; Kuczyk M; Demkow T; Bearz A; Shapiro J; Strauss UP; Porta C
    BJU Int; 2017 Jun; 119(6):846-853. PubMed ID: 27981711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Bailey EB; Tantravahi SK; Poole A; Agarwal AM; Straubhar AM; Batten JA; Patel SB; Wells CE; Stenehjem DD; Agarwal N
    Clin Genitourin Cancer; 2015 Jun; 13(3):e131-7. PubMed ID: 25497584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.
    Zhu AX; Finn RS; Mulcahy M; Gurtler J; Sun W; Schwartz JD; Dalal RP; Joshi A; Hozak RR; Xu Y; Ancukiewicz M; Jain RK; Nugent FW; Duda DG; Stuart K
    Clin Cancer Res; 2013 Dec; 19(23):6614-23. PubMed ID: 24088738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.
    Nadal R; Amin A; Geynisman DM; Voss MH; Weinstock M; Doyle J; Zhang Z; Viudez A; Plimack ER; McDermott DF; Motzer R; Rini B; Hammers HJ
    Ann Oncol; 2016 Jul; 27(7):1304-11. PubMed ID: 27059553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.
    Koie T; Ohyama C; Yoneyama T; Yamamoto H; Imai A; Hatakeyama S; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    BMC Urol; 2015 Apr; 15():32. PubMed ID: 25887125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
    Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Ou SS; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
    J Clin Oncol; 2008 Nov; 26(33):5422-8. PubMed ID: 18936475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
    Motzer RJ; Rini BI; McDermott DF; Redman BG; Kuzel TM; Harrison MR; Vaishampayan UN; Drabkin HA; George S; Logan TF; Margolin KA; Plimack ER; Lambert AM; Waxman IM; Hammers HJ
    J Clin Oncol; 2015 May; 33(13):1430-7. PubMed ID: 25452452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
    Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
    Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.